PetVivo Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Innovative joint health products are gaining traction among veterinarians for their multimodal benefits and ability to reduce reliance on pharmaceuticals. Strategic global distribution and upcoming clinical milestones are expected to drive further adoption and expansion.
-
Revenue for the nine months was $887,000, down 2% year-over-year, with a shift toward lower-margin products and an 81% reduction in total liabilities. Strategic alliances, new AI-driven platforms, and international expansion are expected to drive future growth.
-
Achieved record quarterly and first-half revenues, driven by strong distributor sales and new product launches. Expanded internationally, reduced liabilities, and advanced strategic partnerships and AI initiatives, with continued robust growth expected for fiscal 2026.
-
Revenue grew 141% year-over-year to $298,000, driven by expanded distributor sales and new product launches. Operating loss and net loss both improved, while cash position strengthened through financing. Strategic partnerships and product innovation position the company for continued growth.
Fiscal Year 2025
-
Spryng and PrecisePRP offer regenerative, long-lasting solutions for osteoarthritis in companion animals, supported by strong clinical results, broad distribution, and a robust IP portfolio. Strategic partnerships, international expansion, and ongoing R&D position the company for growth.
-
Fiscal 2025 delivered 17% revenue growth, improved margins, and reduced losses, driven by distributor expansion, cost controls, and new partnerships. Strategic financing and innovative product launches position the company for continued growth in a rapidly expanding animal health market.
-
Q3 saw a 191% sequential revenue jump to $583,000, driven by expanded distribution, though revenue dipped 2% year-over-year. Gross margin held at 89.5%, net loss narrowed, and new capital was raised to support growth and product launches.
-
Board and auditor appointments were ratified, and Spryng continues to gain traction in the veterinary market with strong clinical results, expanded distribution, and ambitious sales growth targets. Financials remain robust with high margins and a flexible capital strategy.
-
Q2 FY2025 saw 62% sequential revenue growth, driven by distributor sales and cost reductions, with gross margin steady at 89.5%. The company targets over 1,500 clinics by year-end and expects FY2025 revenue to grow over 50% year-over-year.
-
Revenue grew 6% to $124,000 in Q1 2025, driven by distributor sales and expansion to 800+ clinics. Gross margin remained high at 89.5%, operating expenses fell 28%, and net loss improved to $2 million. FY2025 revenue is forecast at $1.5–$2 million, with continued market and clinical expansion.
Fiscal Year 2024
-
Fiscal 2024 revenue grew 6% to $969,000, driven by distributor expansion and strong Spryng sales. Operating expenses rose 20%, leading to a net loss of $11 million. Cost reductions, new clinical data, and expanded partnerships position the company for improved performance.